RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference.

RxSight’s management is scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  256.30
+12.08 (4.95%)
AAPL  267.75
-2.62 (-0.97%)
AMD  256.15
+0.03 (0.01%)
BAC  52.88
-0.58 (-1.08%)
GOOG  281.80
-0.02 (-0.01%)
META  655.20
+6.85 (1.06%)
MSFT  520.71
+2.90 (0.56%)
NVDA  207.81
+5.32 (2.63%)
ORCL  258.68
-3.94 (-1.50%)
TSLA  470.75
+14.19 (3.11%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.